APLT (Applied Therapeutics) Ending Cash Position : $79.40 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Applied Therapeutics Ending Cash Position?

Applied Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2024 was $79.40 Mil.

Applied Therapeutics's quarterly Ending Cash Position declined from Jun. 2024 ($122.20 Mil) to Sep. 2024 ($98.87 Mil) and declined from Sep. 2024 ($98.87 Mil) to Dec. 2024 ($79.40 Mil).

Applied Therapeutics's annual Ending Cash Position increased from Dec. 2022 ($16.66 Mil) to Dec. 2023 ($49.90 Mil) and increased from Dec. 2023 ($49.90 Mil) to Dec. 2024 ($79.40 Mil).

Applied Therapeutics Ending Cash Position Historical Data

The historical data trend for Applied Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Therapeutics Ending Cash Position Chart

Applied Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

57.47

53.89

16.66

49.90

79.40

Applied Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															49.90	146.48	122.20	98.87	79.40

Applied Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Applied Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	49.898	+	29.5
	=	79.40

Applied Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	98.867	+	-19.469
	=	79.40

Applied Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Applied Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Applied Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Therapeutics Inc (NAS:APLT) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

2UV:Germany 2UV:Germany

Address

545 Fifth Avenue, Suite 1400, New York, NY, USA, 10017

Website

https://www.appliedtherapeutics.com

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Executives

Riccardo Perfetti	officer: Chief Medical Officer	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Leslie D. Funtleyder	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Shoshana Shendelman	director, 10 percent owner, officer: President and CEO	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Alexandria Real Estate Equities, Inc.	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101
Adam Hansard	officer: Chief Commercial Officer	C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE, SUITE 1400, NEW YORK NY 10017
Stacy J. Kanter	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Catherine Thorpe	officer: Chief Accounting Officer	545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Chids Mahadevan	officer: Chief Accounting Officer	C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Steven A. Ortega	officer: Principal Accounting Officer	C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Charles Silberstein	officer: Chief Financial Officer	C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Joel S Marcus	director	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Alexandria Equities No. 7, Llc	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101
Jay S Skyler	director	DANCE BIOPHARM INC., 150 NORTH HILL DRIVE, SUITE 24, BRISBANE CA 94005
Alexandria Venture Investments, Llc	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101
Teena Lerner	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173